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ABSTRACT
Background. The locus coeruleus (LC) is themajor noradrenergic source in the central
nervous system. Structural alterations in the LC contribute to the pathophysiology
of different neuropsychiatric disorders, which may increase to a variable extent the
likelihood of developing neurodegenerative conditions. The characterization of such
alterations may therefore help to predict progression to neurodegenerative disorders.
Despite the LC cannot be visualized with conventional magnetic resonance imaging
(MRI), specific MRI sequences have been developed to infer its structural integrity.
Methods.We quantified LC signalContrast Ratios (LCCRs) in late-lifemajor depressive
disorder (MDD) (n= 37, 9 with comorbid aMCI), amnestic Mild Cognitive Impair-
ment (aMCI) (n= 21, without comorbid MDD), and healthy controls (HCs) (n= 31),
and also assessed the putative modulatory effects of comorbidities and other clinical
variables.
Results. LCCRs were lower in MDD compared to aMCI and HCs. While no effects of
aMCI comorbidity were observed, lower LCCRs were specifically observed in patients
taking serotonin/norepinephrine reuptake inhibitors (SNRIs).
Conclusion. Our results do not support the hypothesis that lower LCCRs characterize
the different clinical groups that may eventually develop a neurodegenerative disorder.
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Conversely, our results were specifically observed in patients with late-life MDD
taking SNRIs. Further research with larger samples is warranted to ascertain whether
medication or particular clinical features of patients taking SNRIs are associated with
changes in LC neurons.
Subjects Neuroscience, Cognitive Disorders, Psychiatry and Psychology, Radiology and Medical
Imaging
Keywords Major depressive disorder, Amnestic mild cognitive impairment, Locus coeruleus,
Magnetic resonance imaging, Neuromelanin, Serotonin/norepinephrine reuptake inhibitors
INTRODUCTION
The Locus Coeruleus (LC) is a small pontine nucleus with the largest group of
noradrenergic (NA) neurons in the central nervous system (CNS) (Berridge & Waterhouse,
2003; Dahlstroem & Fuxe, 1964). Its ascending and descending projections modulate
neuronal activity in numerous targets throughout the CNS (Loughlin, Foote & Fallon,
1982; Loughlin, Foote & Grzanna, 1986; Loughlin, Foote & Bloom, 1986; Samuels & Szabadi,
2008). Different studies suggest that alterations in the LC, and, hence, in its projection
network, may critically contribute to the onset as well as to the course and symptom profile
of a range of neurological and psychiatric disorders (Betts et al., 2019; Charney, 1998;
Delgado & Moreno, 2000; Gannon et al., 2015; Leonard, 1997). Specifically, the LC has been
suggested to be one of the initial sites of appearance of pathologically altered tau aggregates
in preclinical stages of Alzheimer’s disease (AD) (Braak et al., 2011; Braak & Del Tredici,
2015; Zarow et al., 2003), leading to compensatory increases in α2A adrenergic receptor
levels in regions receiving noradrenergic input (Andrés-Benito et al., 2017). Moreover, there
is evidence that loss of noradrenergic input exacerbates AD progression (Marien, Colpaert
& Rosenquist, 2004; Heneka et al., 2006; Grudzien et al., 2007).
One of the major limitations to investigate the role of the LC in brain disorders with
in-vivo non-invasive techniques is that the LC is difficult to visualize with conventional
magnetic resonance imaging (MRI) techniques. However, Sasaki et al. (2006) identified
the LC in vivo as two bilateral hyperintensities adjacent to the floor of the fourth ventricle
adapting the parameters of a traditional 2D T1-weighted fast spin echo sequence (for
instance, using a higher number of averages and a high in-plane resolution with a large
slice thickness). Themolecular underpinnings of such hyperintense signal are still unknown
(Betts et al., 2019), although it was originally thought to be related with the accumulation
of neuromelanin in LC neurons.
Neuromelanin is a dark polymer pigment formed as a byproduct of catecholamine
metabolism, and it can be found in the LC and substantia nigra pars compacta. The function
of this macromolecule is not entirely known, but it has been shown that neuromelanin
accumulates throughout life in noradrenergic LC neurons, binding to metals such as iron
and copper (Enochs et al., 1989; Enochs et al., 1997; Trujillo et al., 2017). Due to its ability to
chelate metals, neuromelanin could be acting as a paramagnetic agent (Tosk et al., 1992),
and perhaps neuromelanin could be a paramagnetic agent itself (Shima et al., 1997). These
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properties initially led some authors to hypothesize that neuromelanin could be causing
the T1 shortening effects generating the LC contrast in fast spin echo T1 sequences (Sasaki
et al., 2006).
Moreover, using MRI and post mortem histology, Keren et al. (2015) showed that
T1-weighted LC hyperintensities co-localized with LC neurons with high neuromelanin
concentration. Nevertheless, more recent research suggested that it is unlikely that LC
hyperintensities are reflecting neuromelanin accumulation, but rather water content or
general neuronal density (Watanabe et al., 2019). In this sense, throughout the manuscript,
we will avoid using the term neuromelanin-sensitive MRI, although it may be concluded
from the literature that LC MRI contrast ratios (LCCRs) seem to be a valid approximation
to infer structural integrity of the LC (Betts et al., 2019).
There have been different reports of an overall lower LC signal in different
neuropsychiatric conditions, such as major depressive disorder (MDD) (Sasaki et al.,
2010; Shibata et al., 2008), schizophrenia (Shibata et al., 2008), amnestic mild cognitive
impairment (aMCI) (Takahashi et al., 2015), and Alzheimer’s or Parkinson’s disease
(Sasaki et al., 2006; Isaias et al., 2016; Matsuura et al., 2013; Miyoshi et al., 2013; Mukai et
al., 2013; Ohtsuka et al., 2014), among others (for a review see Liu et al., 2017). It is not
clear, however, to what extent such alterations show diagnostic specificity, which might be
useful for clinical purposes (e.g., differential diagnosis, treatment selection, or prediction
of clinical course). This could be important for disorders with partially overlapping clinical
manifestations, such as late-life MDD and aMCI, two conditions typically appearing
between the seventh and the eighth decades of life (Panza et al., 2010; Steffens, 2012).
People suffering from late-life MDD or aMCI have an increased risk for the later
development of AD. Nevertheless, while aMCI is a common prodromal stage of AD, with
a progression rate to AD estimated between 6% to 25% per year (Petersen et al., 2001)
(for a review see Hermida et al., 2012), late-life MDD is not that robustly associated with
dementia onset, and results have been more heterogeneous. Overall, research suggests
that people suffering from late-life MDD have an approximately twofold increased risk of
developing AD (Byers & Yaffe, 2011), although it is not clear whether depression is only a
risk factor or may be considered a prodromal symptom of dementia (Byers & Yaffe, 2011).
Interestingly, moreover, co-occurrence of aMCI and depression seems to increase even
more the probability to develop to AD, suggesting that both conditions have an additive
or synergic effect (Modrego & Ferrandez, 2004; Gabryelewicz et al., 2007). In this context,
it is not clear whether LC MRI intensity discriminates between these disorders and their
comorbidity, and, therefore, to what extent this measurement could contribute to identify
subjects at a higher risk of developing a neurodegenerative disorder.
In this study, we aimed at comparing LC MRI intensity between patients with late-life
MDD and individuals with aMCI, which, for reference purposes, were also compared to a
group of healthy controls (HCs). Moreover, as a secondary aim, we specifically assessed a
group of individuals presenting comorbidity between the two diagnoses, and evaluated the
modulatory effect on our findings of medication and other clinical variables. According
to previous literature, we hypothesized that LC MRI intensity will discriminate between
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the clinical groups and HCs, and also across patients with late-life MDD, aMCI and a
comorbid presentation of both disorders.
MATERIALS & METHODS
Participants
The sample consisted of 89 individuals between 60 and 76 years of age. These were divided
into three groups: 37 patients with a primary diagnosis of late-life MDD (11 males, mean
age [standard deviation, SD]: 68 [4.1] years), 21 subjects with aMCI (9 males, mean age
[SD]: 71.5 [2.7] years), and 31 HCs from the same geographical area (11 males, mean age
[SD]: 67.7 [4.1] years). Subjects from the clinical groups were consecutively recruited from
the Psychiatry and Neurology Departments of Bellvitge University Hospital (Barcelona,
Spain), and HCs through advertisements and word-of-mouth. All participants were
interviewed with the Mini-International Neuropsychiatric Interview (MINI) (Sheehan
et al., 1998). Major depressive disorder diagnoses were established by two experienced
psychiatrists (VS and MU) according to DSM-IV-TR criteria, and disorder severity was
estimated with the Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960) and the
Geriatric Depression Scale (GDS) (Sheikh & Yesavage, 1986; Yesavage et al., 1982), which
were, however, not used for diagnostic purposes. Amnestic MCI diagnoses were based on
a syndromic categorical cognitive staging approach rather than on the use of biomarkers
(Jack et al., 2018). Diagnosis was established by consensus of two experienced neurologists
(JG and RR) and one neuropsychologist (IR) following Petersen criteria (Petersen, 2004),
including: (1) complaints of memory loss confirmed by informants, (2) objective long-term
memory impairments (scores 1.5 SD below mean age and education adjusted normative
values in the delayed recall test from the Wechsler Memory Scale III (WMS-III) (Wechsler,
2004) and the brief neuropsychological battery NBACE (Alegret et al., 2012)), (3) preserved
general cognitive functioning (i.e., scores higher than 23 for literate people and higher than
18 for illiterates in the Spanish version of the Mini Mental State Examination (MMSE)
(Folstein, Folstein & McHugh, 1975)), and (4) intact or mildly impaired daily living abilities
(Clinical Dementia Rating (CDR) (Morris, 1993) scores of 0.5). All participants were
also administered the Vocabulary subtest of the Wechsler Adult Intelligence Scale, Third
Edition (WAIS-III) (Wechsler, 1999), to estimate the premorbid intelligence quotient
(IQ) (García-Lorenzo et al., 2013). Importantly, aMCI participants did not present past or
current comorbidity with MDD, while nine out of the 37 patients with MDD presented a
comorbid aMCI diagnosis. In all cases, medication was not changed and was kept at stable
doses for at least one month before MRI acquisition. Fourteen out of 21 aMCI subjects
were taking antidepressants for conditions other thanMDD, such as impaired psychosocial
adjustment, insomnia or headache. Table 1 summarizes the sociodemographic and clinical
characteristics of the study sample, while information about antidepressant medication is
provided in Table 2.
Exclusion criteria for the study participants included: (1) ages <60 or >76 years,
(2) past or current diagnosis of other major psychiatric disorders including substance
abuse or dependence (except nicotine), (3) intellectual disability/neurodevelopmental
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Age, years; mean (SD) [range] 68 (4.1) [60–74] 71.5 (2.7) [67–76] 67.7 (4.1) [60–75] H = 1.38 (0.001) 2
Sex, male; n (%) 11 (29.7) 9 (42.9) 11 (35.5) X 2= 1.03 (0.599) 2
Clinical characteristics
HDRS; mean (SD) [range] 12.1 (7.1) [1–28] 3.8 (3) [0–8] 1.3 (2.8) [0–15] H = 50.85 (<0.0001) 2
GDS; mean (SD) [range] 5.6 (4.3) [0–13] 2.3 (2.2) [0–9] 1.23 (2.3) [0–12] H = 27.7 (<0.0001) 2
MMSE; mean (SD) [range]b 25.9 (3.3) [13–30] 25.8 (2.6) [20–29] 28.9 (1.49) [24–30] H = 32.68 (<0.0001) 2
Long Term Memoryc; mean (SD) [range] 5.08 (2.54) [0-10] 1.95 (1.28) [0–4] 8.32 (1.72) [6–12] H = 53.93 (<0.0001) 2
Notes.
Abbreviations: aMCI, amnestic Mild Cognitive Impairment; df, degrees of freedom; GDS, Geriatric Depression Scale; HDRS, Hamilton Depression Rating Scale; MDD, late-
life Major Depression Disorder; MMSE, Mini-Mental State Examination; SD, Standard Deviation.
aStatistic value corresponds to Kruskal-Wallis H test for continuous variables and chi-square test for categorical variables.
bThe cut-off in the Spanish version of the MMSE (Lobo et al., 1999) is adjusted for age and schooling years. Scores higher than 23 for literate people and higher than 18 for illiter-
ates indicate preserved general cognitive functioning.
cEvaluated with the delayed recall test from the Wechsler Memory Scale III (WMS-III).
Table 2 Antidepressant treatment at the time of the study.
n (%) [dose-range in mg]
MDD patients n= 37 aMCI patients n= 21
Tricyclics
Clomipramine 2 (5.4) [37.5–75] 0 (0) [0]
Imipramine 2 (5.4) [75–175] 0 (0) [0]
Amitriptyline 1 (2.7) [25] 2 (9.5) [20–25]
Selective serotonin reuptake inhibitors (SSRIs)
Sertraline 1 (2.7) [200] 0 (0) [0]
Citalopram 2 (5.4) [10] 4 (19.1) [10–20]
Paroxetine 3 (8.1) [20–30] 0 (0) [0]
Serotonin–norepinephrine reuptake inhibitors (SNRIs)
Venlafaxine 12 (32.4) [75–300] 0 (0) [0]
Duloxetine 11 (29.7) [60–120] 0 (0) [0]
Desvenlafaxine 2 (5.4) [50–100] 0 (0) [0]
Other antidepressants
Mirtazapine 7 (18.9) [15–30] 2 (9.5) [7.5–15]
Bupropion 5 (13.5) [150–300] 0 (0) [0]
Vortioxetine 1 (2.7) [10] 0 (0) [0]
Agomelatine 2 (5.4) [25] 0 (0) [0]
Trazodone 4 (10.8) [50–100] 7 (33.3) [50–100]
Notes.
Abbreviations: aMCI, amnestic Mild Cognitive Impairment; MDD, late-life Major Depression Disorder; SD, Standard Devi-
ation.
disorders, (4) neurological disorders, (5) Hachinski Ischemic Score >5 to exclude
individuals with a high probability of vascular-derived cognitive deficits, (6) presence
of dementia according to the DSM-IV-TR criteria and/or a CDR score>1, (7) severe
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medical conditions, (8) electroconvulsive therapy in the previous year, (9) conditions
preventing neuropsychological assessment or MRI procedures (e.g., blindness, deafness,
claustrophobia, pacemakers or cochlear implants), and (10) gross abnormalities in the
MRI scan. We also evaluated the presence of vascular pathology in our brain region of
interest (pons), finding no significant alterations preventing accurate image processing and
analysis.
The study was approved by The Clinical Research Ethics Committee (CEIC) of Bellvitge
UniversityHospital (reference PR156/15, February 17th 2016) andperformed in accordance
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later
amendments (revised in 2013). All participants gavewritten informed consent to participate
in the study.
MRI scanning protocol
All scans were performed in a 3T Philips Ingenia Scanner (Koninklijke Philips N.V.,
Netherlands), using a 32-channel head coil. Following previous reports (Sasaki et al.,
2006), we obtained a modified T1-weighted fast spin-echo sequence of the brainstem
for LC visualization (see examples of individual participants in Fig. S1). Acquisition
parameters were: TR 600 ms, TE 15 ms, 15 slices; 2.5 mm slice thickness, 0 mm gap,
matrix size 404×250, FOV 170×170 mm2, acquisition voxel size 0.42×0.68×2.5 mm3,
reconstructed voxel size 0.39×0.39×2.5 mm3, FA 900, 6 NEX (online averaging), and
a total scan time of 15 min. The sections were acquired in the oblique axial direction
perpendicular to the floor of the fourth ventricle, covering from the posterior commissure
to the inferior border of the pons. Axial T1-weighted turbo-gradient-echo high-resolution
whole-brain anatomical images (233 slices, TR = 10.46 ms, TE = 4.79 ms, flip angle =
8◦, FOV = 240×240, 0.75×0.75 mm isotropic voxels) were additionally obtained for
pre-processing purposes and to discard gross structural pathology. Finally, we also obtained
a 2D FLAIR sequence in the axial plane (38 slices, TR= 10,000ms, TE= 140ms, TI= 2,700
ms, FOV = 230 ×186, 0.8×1×3 mm voxels, 0.6 mm gap) to assess vascular pathology
and other potential radiological abnormalities. Throughout the acquisition protocol, we
used foam pads and made sure that patients’ head was comfortably placed within the head
coil to avoid excessive movement.
Localization and quantification of the LC
To quantify LC MRI intensity, we used a semi-automated ‘‘in-house’’ algorithm. We
focused our analysis on the region of the dorsal pons. Specifically, our approach was based
on previous studies (García-Lorenzo et al., 2013) and consisted of two main steps:
A): Delineation of regions of interest (ROIs): We defined four rectangular ROIs onto the
Montreal Neurological Institute 152 [MNI 152] template (0.5 mm isotropic resolution)
using the Statistical Parametric Mapping (SPM 12) software (http://www.fil.ion.ucl.ac.uk/
spm/). Specifically, two of these ROIs were symmetrically located in the left and right areas
of the dorsal pons where the LC is expected to be found, adjacent to the floor of the fourth
ventricle and extending to the level of the inferior colliculi. Importantly, we explicitly
avoided including in these ROIs other hyperintense regions, such as the substantia nigra,
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to ensure that the LC was the highest signal intensity. The other two ROIs covered the mid
portions of the adjacent left and right pontine tegmentum (again, avoiding the inclusion
of the substantia nigra), and were used as a reference to standardize LC intensity values
(see below). These ROIs, drawn in normalized MNI space, were then denormalized to the
native space of each participant. However, due to the small size of the locus coeruleus and
the anisotropic voxel size of the images, the LC sensitive sequence was not manipulated
and was used as the target image, therefore avoiding interpolation artifacts and preserving
the original signal. Consequently, we first linearly coregistered, for each participant and in
native space, thewhole-brainT1 image to the LC sensitive image.Next, the tissue probability
map (TPM) and the four ROIs inMNI space were coregistered (linear coregistration) to the
whole-brain T1 image from the previous step, and such individual whole-brain T1 images
were non-linearly normalized to the coregistered TPM, which generated a deformation
field. The inverse of the deformation field was calculated by using the deformation function
in SPM, taking the LC sensitive image as the image to base the inversion on. The four ROIs
were then non-linearly denormalized to each participant native space by applying the
inverse of the deformation fields with a 4th degree b-spline interpolation. Finally, these
ROIs were binarized using a trilinear interpolation and a cut-off value of 0.1 (using the
ImCalc function; i1>0.1) in order to better delimitate the ROI area to be extracted; then,
each binarized ROI was applied to the LC-sensitive image (ImCalc function; i1.*i2), which
effectively removed from these images all the information outside the ROIs. Therefore, the
final output of the process were 4 images for participant, in native space, corresponding
to the projection of each ROI into the LC-sensitive image. This approach is summarized
in Fig. S2. Likewise, Fig. S3 displays the accuracy of the coregistration between the LC, the
reference ROI and the brainstem structures in native space.
B): Quantification of the LC signal with a growing algorithm. This second step was
implemented using an in-house growing algorithm, programmed in MATLAB version
9.3 (R2017b) (The MathWorks Inc, Natick, Massachusetts), which was applied to the
final output images from step A) that encompassed the LC region. Specifically, following
García-Lorenzo et al. (2013), who defined LC as ‘‘the area of 10-connected voxels with
the brightest intensity’’, the current algorithm searched throughout these images the 10
clusters of 10 contiguous voxels (face and/or edge and/or vertex contiguity) with the highest
intensity (highest mean intensity of the cluster) (see Fig. 1). These clusters were visually
inspected for their anatomical correspondence with the region of the LC. In case the cluster
with highest intensity was deemed to be outside the LC region, the second cluster was
inspected, and so on. Finally, we obtained, for each participant, the 10-voxels cluster of
highest signal intensity within the LC region, as well as the mean intensity value and peak
coordinate for this cluster (SLC). In agreement with our interest in assessing the intensity
of LC, this 10-voxels average represents a good estimation of mean LC intensity and its
presumed neural integrity (Liu et al., 2017). This is different from a volume measure of the
nucleus; also, we did not discriminate intensities across the different territories of the LC
(García-Lorenzo et al., 2013).
The mean signal intensity from the reference pontine tegmentum cluster was also
obtained for each participant (SREF). This value was used to control for putative differences
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Figure 1 Visualization and localization of the LC and the reference region. (A) Axial, coronal and sagit-
tal views of the dorsal pons from the modified fast spin-echo T1 sequence of a representative participant
(see text for details). The LC can be identified in each hemisphere as an hyperintense structure (red ar-
rows). (B) Axial, coronal and sagittal views of the dorsal pons from the high-resolution whole-brain T1 se-
quence of the same participant, depicting, in red, the 10 most intense LC voxels as identified by the grow-
ing algorithm. The denormalized ROI of the LC and reference regions are depicted as red (encompassing
the 10 most intense LC voxels) and blue contours, respectively.
Full-size DOI: 10.7717/peerj.10828/fig-1
in global signal intensity across participants. We used the following formula to calculate the
LC contrast ratio (CR) (Liu et al., 2017): CR = (SLC – SREF) / SREF. This CR was calculated
for each participant and for both LC (left and right), obtaining two different CRs for
each participant (CRLeft and CRRight). However, as we did not expect interhemispheric
differences, and in order to simplify statistical analyses, we averaged left and right CRs
using the following formula: average LCCR= (CRLeft + CRRight) / 2. The average LCCR was
the final variable used in the statistical analysis.
Statistical analysis
Differences in demographical and clinical features were contrasted across the three study
groups with the Kruskal-Wallis test for continuous variables and the Chi-Square test for
categorical variables. Differences in average LCCRwere also assessed across the study groups
using the Kruskal-Wallis test. Having in mind that LCMRI contrast ratios interact with age
(Liu et al., 2019) and that structural and functional differences between men and women
have been found in this region (Bangasser, Wiersielis & Khantsis, 2016;Mulvey et al., 2018),
average LCCR comparisons were controlled for age and sex. For this, we created a new
variable (standardized residual of average LCCR, sra LCCR) extracting the effect of both
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variables, as non-parametrical tests do not allow nuisance covariates. When the Kruskal-
Wallis test showed significant differences across the three groups, pairwise comparisons
were assessed using the Mann–Whitney’s U test. Moreover, we used Spearman’s Rho (rs)
correlations to evaluate the possible associations between sra LCCR and different clinical
features (i.e., dose and duration of treatments, MMSE).
Finally, we analyzed the modulatory effect of treatment (e.g., treatment type, duration or
dose) on sra LCCR with the Kruskal-Wallis test and Spearman correlations (for categorical
and continuous variables, respectively).When adequate, statistical significancewas adjusted
with a Bonferroni correction for multiple testing. We also calculated Cliff’s δ statistic (Cliff,
1996) to estimate effect sizes.
RESULTS
Data on sociodemographic and clinical characteristics of study participants are displayed in
Table 1. Due to the consecutive recruitment strategy, the groups differed in age (H = 13.38,
p= 0.001, degrees of freedom (df) = 2), with the aMCI group showing the highest mean
age, while the MDD group did not differ from HCs. Also, we found a significant negative
correlation between the right LCCR and age (r s = −0.218, p= 0.04). In any case, as
described above, all analyses were controlled for age and sex.
The Kruskal-Wallis test showed significant across-group (MDD n= 37, aMCI n= 21,
HCs n= 31) differences in sra LCCR (H = 16.64, df = 2, p= 0.001). In post-hoc analyses,
it was observed that MDD subjects displayed a lower sra LCCR in comparison to aMCI
(U = 193, Z =−3.16, p< 0.005, δ (Cliff’s delta effect size) = −0.53) and HCs (U = 281,
Z =−3.60, p< 0.001, δ = −0.51). See Table 3 and Fig. 2A. Importantly, our groups did
not differ in the signal intensity from the reference region (H = 3.47, df = 2, p= 0.177),
and, therefore, sra LCCR differences were attributable to differences in LC signal intensity.
We did not observe any significant effects of aMCI comorbidity in patients with
MDD, since no significant differences were found in sra LCCR between the subgroup of
MDD without aMCI (n= 28) and MDD patients with comorbid aMCI (n= 9) (U = 95,
Z =−1.10, p= 0.272, δ=−0.25). Likewise, both groups significantly differed from HCs
and the aMCI group (see Fig. S4). Moreover, as depicted in Fig. S5, we observed no
significant correlations between sra LCCR values and MMSE scores for any of the study
groups.
When evaluating the possible effects ofmedication (see Fig. 2B),we observed that patients
withMDD taking Serotonin andNorepinephrine Reuptake Inhibitors (SNRIs) (n= 25) had
a significantly lower sra LCCR compared to HCs (n= 31) (U = 143, Z =−4.03, p< 0.001,
δ= −0.63) and to aMCI patients (n= 21) (U = 94, Z =−3.72, p< 0.001, δ= −0.64).
However, we did not observe significant differences in sra LCCR between MDD patients
taking (n= 25) and not taking (n= 12) SNRIs, although sra LCCR of MDDs patients not
taking SNRIs did not differ from HCs (n= 31) (U = 138, Z =−1.30, p= 0.194, δ=−0.26)
or aMCI patients (n= 21) (U = 99, Z =−1.01, p= 0.312, δ= −0.21). Although it was
not possible to properly evaluate the effect of SNRIs due to the small sample size of the
group of MDD subjects exclusively taking SNRIs (n= 5), comparing the group of MDD
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Average LC Contrast Ratio
(sra LCCR)
Intensity: mean (SD)
MDD whole group (n= 37) 0.194 (0.059) −0.450 (0.0728)
MDD with aMCI (n= 9) 0.195 (0.084 −0.474 (1.016)
MDD without aMCI (n= 28) 0.194 (0.052) −0.442 (0.633)
aMCI (n= 21) 0.234 (0.079) 0.257 (0.946)
HCs (n= 31) 0.260 (0.093) 0.363 (1.096)
MDD split according to SNRIs treatment
MDD taking SNRIs (n= 25) 0.180 (0.045) −0.621 (0.538)
MDD not taking SNRIs (n= 12) 0.224 (0.076) −0.094 (0.947)
Notes.
Abbreviations: aMCI, amnestic Mild Cognitive Impairment; HCs, Healthy Controls; LC, Locus Coeruleus; MDD, late-life
Major Depressive Disorder; SD, Standard Deviation; SNRIs, Serotonin and Norepinephrine reuptake inhibitors.
patients taking SNRIs alone with the rest ofMDDpatients (n= 32) and with patients taking
SNRIs and other psychiatric medications (n= 20) we did not find significant differences
(U = 60, Z =−0.89, p= 0.374, δ= −0.25; and U = 43, Z =−0.48, p= 0.634, δ= −0.14).
Importantly, we did not find any significant differences between MDD patients taking
and not taking SNRIs in clinical variables such as severity, disease duration or treatment
resistance. These results are presented in Table S1.
Importantly, we repeated the analysis by subdividing the MDD group into those who
took (n= 31) and those who did not take (n= 6) medications with noradrenergic effect
(SNRIs + Tricyclics + Mirtazapine + Vortioxetine + Agomelatine + Bupropion), obtaining
similar results: MDD taking noradrenergic medication had a significant lower sra LCCR
compared to HCs (n= 31) (U = 209, Z =−3.82, p< 0.001, δ= −0.57) and the aMCI
group (n= 21) (U = 143, Z =−3.40, p< 0.005, δ= −0.56). Again, although we did
not observe significant differences in sra LCCR between MDD patients taking and not
taking noradrenergic medications, sra LCCR of MDD patients not taking noradrenergic
medications did not differ from HCs (n= 31) (U = 72, Z =−0.86, p= 0.387, δ= −0.23)
or aMCI patients (n= 21) (U = 50, Z =−0.76, p= 0.448, δ=−0.21). Also, MDD patients
exclusively taking noradrenergic medications other than SNRIs (n= 6) did not differ
from patients taking SNRIs (n= 25), not taking noradrenergic medications (n= 6), or the
HCs and aMCI groups (see Table S2). Finally, we also assessed whether subjects taking
adrenergic medication for non-mental health purposes (i.e., beta-blockers; 4 HCs, 1 aMCI
and 7 MDD) showed differences in sra LCCRs, finding non-significant effects.
Unfortunately, it was not possible to properly evaluate the effect of Selective Serotonin
Reuptake Inhibitors (SSRIs) due to the small sample size of the group of MDD subjects
exclusively taking SSRIs (n= 3). Nevertheless, comparing the group of MDD patients
taking SSRIs alone or in combination with other medications (n= 6) with HCs and
patients with aMCI, we did not find significant differences after Bonferroni correction
(U = 32, Z =−2.51, p= 0.012, δ= −0.66, and U = 20, Z =−2.51, p= 0.012, δ= −0.68;
Bonferroni p thresholded at p= 0.0083).
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Figure 2 Boxplots depicting the average LC Contrast Ratios. Boxplots showing the average LCCR (age
and sex adjusted, sra LCCR) for the different study groups. The individual values (dots) are overlaid for
reference. (A) Boxplots of the average LCCR for the three main study groups; (B) Boxplots of the average
LCCR splitting patients with late-life MDD as a function of SNRIs treatment. aMCI, amnestic type Mild
Cognitive Impairment; HCs, Healthy Controls; LCCR, Locus Coeruleus Contrast Ratio; MDD, late-life
Major Depressive Disorder. ** p ≤ 0.005, *** p ≤ 0.001. All results remained significant after excluding
outlier values.
Full-size DOI: 10.7717/peerj.10828/fig-2
Finally, we did not find significant correlations between dose or duration of any of the
treatments and sra LCCR.
Unless otherwise indicated, all the above significant findings survived Bonferroni
correction for multiple comparisons.
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DISCUSSION
Our study compared LC MRI signal intensity between two groups of subjects with brain
disorders conferring an increased risk for dementia. We observed that average LCCR
was significantly lower in late-life MDD patients compared to aMCI and HC groups, but
no evidence of additive effects between depression and aMCI. Moreover, such lower LC
intensity was associated with the medication used by participants, since significant effects
were indeed only observed in the subgroup of MDD patients taking SNRIs.
Our results are in overall agreement with the monoamine hypothesis of depression
(Delgado, 2000), which suggests that MDD patients show significant alterations in
monoaminergic neurotransmission, and, more specifically, with previous neuroimaging
studies reporting a lower LC intensity in patients withMDD compared toHCs (Sasaki et al.,
2010; Shibata et al., 2008). Previous reports have shown that NA plays a major role in the
pathophysiology of depression (Delgado & Moreno, 2000; Moret & Briley, 2011), with the
LC projecting to emotion- and cognition-related areas implicated in the pathophysiology
of depression (Stahl, 2008).
In any case, we also observed that this lower LC intensity was specific of MDD patients
taking dual action antidepressants (SNRIs). There could be two different explanations for
this. On the one hand, if we consider that LCMRI contrast is directly or indirectly associated
to the accumulation of neuromelanin compounds (Betts et al., 2019), we could speculate
about the nature of such accumulation and the molecular effect of dual antidepressant
treatment. Neuromelanin is an autophagic byproduct resulting from the metabolism of
NA and other catecholamines (German et al., 1988; Graham, 1979), and its accumulation
increases with age in different brain nuclei, such as the substantia nigra and the LC
(Clewett et al., 2016). Since SNRIs antidepressants inhibit NA reuptake, the levels of this
neurotransmitter are increased at the synaptic cleft, what could lead to a decrease in
intracellular NA synthesis and metabolism. Sustained over time, this decrease in NA
synthesis and degradation could result in a decreased neuromelanin accumulation in the
LC. However, this could have been a strong argument if significant correlations between
LC signal intensity and SNRIs treatment dose and duration had been observed, but this was
not the case in our study. Moreover, there are no evidences of the existence of an enzymatic
mechanism capable of inducing degradation or removing neuromelanin (Fedorow et al.,
2006; Halliday et al., 2006), and, therefore, it is not possible to argue that noradrenergic
antidepressants may be promoting neuromelanin degradation in LC neurons.
On the other hand, the possibility exists that particular clinical features of the subgroup
of MDD subjects who are taking SNRIs might be associated with the lower LCCR in
this group of patients. In our sample, MDD patients taking SNRIs did previously fail to
respond to treatments with SSRIs. Speculatively, this treatment failure could be related to
an impaired NA function reflected in lowerMRI LCCR that required the active modulation
of NA neurotransmission. Although treatment with dual action antidepressant does not
seem to normalize LCCR intensity levels, prospective research on the interaction between
antidepressant medication with noradrenergic action and LC signal intensity, carefully
controlling for doses and treatment duration, is warranted to elucidate this issue.
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Contrary to our initial expectations, we did not observe any significant effect of aMCI
on LC signal intensities, which prevents suggesting LC MRI intensity as a putative risk
imaging marker for AD. These results contradict previous research showing not only an
early loss of LC neurons in AD (Szot et al., 2006), but also lower LC intensity values in
aMCI versus HCs (Takahashi et al., 2015). Critically, however, that study did not exclude
patients with comorbid depression, while our group of aMCI individuals did not show
comorbidity with major depression. Therefore, we propose that MDD symptoms may be
actually more relevantly accounting for lower LC signal intensity. In agreement with this,
we have also observed that the presence of comorbid aMCI in patients with MDD did not
significantly contribute to further lowering LC signal intensities.
This study is not without limitations. First, since we did not obtain data on cerebrospinal
fluid or positron emission tomography imaging biomarkers, we used a syndromic
categorical cognitive staging approach and we cannot confirm that our patients were indeed
from the AD continuum and will ultimately develop AD. Second, longitudinal studies with
larger and carefully characterized samples are highly encouraged in order to better explore
the interactions over time of group findings with clinical and sociodemographic variables.
This will probably allow identifying clinically relevant subgroups of individuals as a
function of their LC signal intensities and contribute to better estimate the likelihood of a
degenerative course. Third, we are not using a quantitative MRI method, although other
MRI sequences, such as Magnetization Transfer (MT), may provide quantitative indices
(Ramani et al., 2002; Sled & Pike, 2001) that have been used for assessing LC integrity
(Trujillo et al., 2019). As many other groups, we used a Spin Echo (SE) sequence for
assessing LC neuronal integrity (Liu et al., 2017), although MT based sequences seem to
be a better option to perform absolute signal quantifications (Trujillo et al., 2019) and to
more precisely localize the LC with isotropic resolution and increased contrast-to-noise
ratio, especially at higher-field strengths (Priovoulos et al., 2018). We performed a relative
quantification taking another brainstem region as the reference area to control for intensity
fluctuations across participants, and, importantly, groups did not significantly differ in the
intensity of this reference region, indicating that our groupdifferences stem fromdifferences
in LC intensity. Nevertheless, further studies combining quantitative and non-quantitative
approaches are probably needed to perform better estimations of neural integrity in the LC
(Betts et al., 2019). Likewise, the present approach did not allow quantifying the volume
of the LC, which would have required performing a manual segmentation of the nucleus,
and, therefore, we can only infer changes in LC integrity from changes in MRI signal
intensity. If such signal intensity is related to neuromelanin accumulation, LC integrity will
be probably reflecting preserved adrenergic activity. By contrast, if such signal is related to
higher neuronal density or water content, as recently suggested (Watanabe et al., 2019), LC
integrity will be reflecting a lack of regional atrophy and/or a good osmotic balance in the
context of a normal neuronal metabolism.
In the context of limitations, it is also important to note that there are studies suggesting
that age-related variance should be considered when exploring structural abnormalities in
the LC (Shibata et al., 2006; Liu et al., 2019). Moreover, these age effects may probably
show a non-homogenous distribution along the rostral-caudal axis of the nucleus
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(Betts et al., 2017; Dahl et al., 2019; Liu et al., 2019). Thus, age-related declines in LCCR
have been mainly observed in the rostral part of the LC in healthy subjects (Liu et al.,
2019), being such decline in rostral LCCRs related to poorer memory performance in
neuropsychological testing (Dahl et al., 2019). Although we controlled for age and sex,
our algorithm did not allow distinguishing between the rostral and the caudal parts of the
nucleus, which may have partially confounded our findings. Moreover, white matter from
the pontine tegmentum, used here as reference, has also been shown to increase its T1
intensity with age, probably as a consequence of the highly protracted cycle of myelination
of this region, extending up to 70 or 80 years of age (Yakovlev & Lecours, 1967). Despite
our statistical control for age, and although our groups did not differ in the signal intensity
of this reference region, this may have also partially confounded our findings.
CONCLUSIONS
To sum up, LC signal intensity does not seem to allow identifying subjects with cognitive
profiles related to prodromal phases of AD. Conversely, it seems to be associated to late-life
MDD. Further research with larger samples should ascertain whether medication aimed
at modulating noradrenergic neurotransmission may be playing a role in these findings
or, conversely, changes in LC neurons are associated with a particular clinical profile
preferentially observed in patients responding to noradrenergic medication. It also remains
to be determined if these findings may contribute to optimizing treatment of patients with
late-life MDD.
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